2,4-Dimethylthieno<3,2-d>pyrimidin | 53827-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2,4-Dimethylthieno<3,2-d>pyrimidin
• 英文别名: 2,4-dimethyl-thieno[3,2-d]pyrimidine；2,4-Dimethylthieno[3,2-d]pyrimidine
• CAS: 53827-37-5
• 化学式: C₈H₈N₂S
• 分子量: 164.231
• InChiKey: PXAKCTYAPVOZQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-<(2-acetyl-3-thienyl)>acetamide 在 氨 作用下， 以 formamide 为溶剂， 生成 2,4-Dimethylthieno<3,2-d>pyrimidin
  参考文献：
  名称：

  Ah-Kow,G. et al., Bulletin de la Societe Chimique de France, 1976, p. 151 - 160

  摘要：

  DOI：

文献信息

• AROMATIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1956009A1

  公开（公告）日：2008-08-13

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  以下公式表示的芳香族化合物或其药用可接受盐： 其中，环A是杂环，环B是碳环、杂环等，G1、G2、G3、G4和G5是CH或N，X是-NH-、-O-、-CH2-等，Y是-CH2-、-CO-、-SO2-等，Z是单键、-CO-、-SO2-、-NH-、-O-、-S-、-CONH-、-SO2NH-等，R2是氢、烷基、烷氧基、卤素等，R3是碳环组、杂环组、烷基等， 作为控制CCR4功能的调节剂，对治疗或治疗支气管哮喘、特应性皮炎等疾病很有用。
• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS
  申请人：Zask Arie

  公开号：US20090098086A1

  公开（公告）日：2009-04-16

  The invention relates to thienopyrimidine and pyrazolopyrimidine compounds of the Formulas (Ia) and (IIa), or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein compositions comprising the compounds, and methods for making and using the compounds.

  该发明涉及Formula (Ia)和Formula (IIa)的噻吡嘧啶和吡唑嘧啶化合物，或其药用可接受的盐，其中组成变量如本文所定义的那样，包括该化合物的组合物，以及制备和使用该化合物的方法。
• INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN

  公开号：US20150344443A1

  公开（公告）日：2015-12-03

  Disclosed are inhibitors of the USP1/UAF1 deubiquitinase complex, for example. of formula (I), wherein R 1 , R 2 , and Q are as defined herein, which are useful in treating diseases such as cancer, and improving the efficacy of DNA damaging agents in cancer treatment. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a heterodimeric deubiquitinase complex in a cell, and a method of enhancing the chemotherapeutic treatment of cancer in a mammal undergoing treatment with an anti cancer agent. Further disclosed is a method of preparing compounds of the invention.

  本发明涉及抑制USP1/UAF1去泛素化酶复合物的抑制剂，例如式（I）中定义的R1、R2和Q，其对于治疗癌症和提高DNA损伤剂在癌症治疗中的疗效非常有用。本发明还涉及一种包含药学适用载体和本发明中至少一种化合物的组合物，一种在细胞中抑制异源二聚体去泛素化酶复合物的方法，以及一种增强正在接受抗癌药物治疗的哺乳动物的化疗治疗的方法。本发明还涉及一种制备本发明化合物的方法。
• Aromatic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182142A1

  公开（公告）日：2009-07-16

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G 1 , G 2 , G 3 , G 4 and G 5 are CH or N, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is a single bond, —CO—, —SO 2 —, —NH—, —O—, —S—, —CONH—, —SO 2 NH—, etc., R 2 is hydrogen, alkyl, alkoxy, halogen, etc., and R 3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  下列的芳香族化合物或其药学上可接受的盐，其化学式如下：其中环A为杂环，环B为碳环、杂环等，G1、G2、G3、G4和G5为CH或N，X为—NH—、—O—、—CH2—等，Y为—CH2—、—CO—、—SO2—等，Z为单键、—CO—、—SO2—、—NH—、—O—、—S—、—CONH—、—SO2NH—等，R2为氢、烷基、烷氧基、卤素等，而R3为碳环基、杂环基、烷基等。该化合物对于控制CCR4功能的作用剂对于治疗或治疗支气管哮喘、特应性皮炎等疾病是有用的。